2017
Obstacles to the Adoption of Biosimilars for Chronic Diseases
Hakim A, Ross JS. Obstacles to the Adoption of Biosimilars for Chronic Diseases. JAMA 2017, 317: 2163-2164. PMID: 28459924, DOI: 10.1001/jama.2017.5202.Commentaries, Editorials and Letters
2014
Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010
Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, Stettin G, Krumholz HM. Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010. JAMA Internal Medicine 2014, 174: 1486-1493. PMID: 25070672, PMCID: PMC4208827, DOI: 10.1001/jamainternmed.2014.3404.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsENHANCE trialEzetimibe useEzetimibe initiationPharmacy benefit managersUse of ezetimibeProgression of atherosclerosisAdults 18 yearsHalf of adultsAtherosclerosis regression trialsPredictors of useBenefit managersEzetimibe monotherapyMonotherapy usersMedication initiationEligible adultsPrescription claimsCholesterol levelsRetrospective analysisMAIN OUTCOMEAdult beneficiariesUS census divisionsDiscontinuationRegression trialsEzetimibe
2013
Prescription-Drug Coupons — No Such Thing as a Free Lunch
Ross JS, Kesselheim AS. Prescription-Drug Coupons — No Such Thing as a Free Lunch. New England Journal Of Medicine 2013, 369: 1188-1189. PMID: 23984672, DOI: 10.1056/nejmp1301993.Commentaries, Editorials and LettersDeductibles and CoinsuranceDrug CostsDrug IndustryDrugs, GenericFees, PharmaceuticalInsurance, Pharmaceutical ServicesPrescription DrugsUnited States